Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

More data on dosing needed for Flutiform

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

SkyePharma receives a 74-day letter from FDA for its asthma treatment Flutiform (fluticasone/formoterol inhalation aerosol), noting that although its NDA is "sufficiently complete," based on FDA's preliminary assessment it is "likely" that further clinical work would be required for approval - specifically to accumulate additional data on dosing. SkyePharma is seeking further clarification of review issues. Flutiform is a fixed-dose combination of formoterol and the inhaled steroid fluticasone in a metered dose inhaler. The U.K.-based drug delivery company is partnering with Abbott in the U.S. and Mundipharma in the EU, where Flutiform is expected to be filed for approval in the first quarter of 2010. The application was submitted to FDA in March 2009 and accepted May 22, 2009

You may also be interested in...



Future of Skyepharma's combination asthma therapy Flutiform is up in the air in the U.S.

Drug delivery specialist SkyePharma issued a statement June 24 saying it is reviewing available options for advancing its asthma therapy Flutiform (fluticasone/formoterol) in the U.S. "It is apparent that the FDA's requirements for approving Flutiform have changed materially during the course of the development program," the company said. FDA told the company in June 2009 that further clinical studies likely would be required for approval and followed up in January with a "complete response" letter (1Pharmaceutical Approvals Monthly, June 1, 2009). Meanwhile, an application to market the asthma drug in Europe, "where the regulatory approach is different," was filed in March and is under review. SkyePharma is partnered with Abbott on the inhaler in the U.S. and with Mundipharma in the EU; Flutiform is in Phase II studies with partner Kyorin in Japan. The U.K.-based company focused on Flutiform in the U.S. after a formoterol inhaler partnered with Novartis gained approval but never went to market because of safety concerns related to single agent inhalers (2"The Pink Sheet," Dec. 22. 2008)

EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments

While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.

US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing

The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.

Topics

UsernamePublicRestriction

Register

ID007083

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel